Duyuru • Feb 07
Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq On February 6, 2023, Rubius Therapeutics, Inc. was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) as of January 23, 2023, and the Staff’s determination that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101, the Company would be delisted at the opening of business on February 15, 2023 unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”) to address the deficiencies and present a plan to regain compliance. The Company plans to timely request a hearing before the Panel, which request will stay any further delisting action by the Staff at least pending the ultimate outcome of the hearing and the expiration of any extension that may be granted by the Panel. The Company’s common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process. As previously disclosed, on July 27, 2022, the Company received written notice from the Staff indicating that, based upon the closing bid price for the Company’s common stock for the previous 30 consecutive business days, the Company no longer satisfied the minimum bid price requirement for continued listing on The Nasdaq Global Select Market and, in accordance with the Nasdaq Listing Rules, was afforded a 180-calendar day grace period, through January 23, 2023 to regain compliance with the rule. The Company did not regain compliance with minimum bid price requirement by January 23, 2023 and, given the Staff’s separate determination that the Company is a public shell, the Staff did not grant the Company a second grace period to do so. Board Change • Nov 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 7 experienced directors. No highly experienced directors. Member of Scientific Advisory Board Bob Langer is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Price Target Changed • Sep 13
Price target increased to US$7.63 Up from US$6.80, the current price target is an average from 4 analysts. New target price is 723% above last closing price of US$0.93. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year. Price Target Changed • Aug 10
Price target increased to US$10.33 Up from US$7.00, the current price target is an average from 5 analysts. New target price is 1,209% above last closing price of US$0.79. Stock is down 97% over the past year. The company is forecast to post a net loss per share of US$1.87 next year compared to a net loss per share of US$2.23 last year. Duyuru • Jul 28
Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Rubius Therapeutics, Inc. announced that they will report Q2, 2022 results at 9:30 AM, US Eastern Standard Time on Aug 09, 2022 Price Target Changed • May 12
Price target decreased to US$7.60 Down from US$8.67, the current price target is an average from 5 analysts. New target price is 513% above last closing price of US$1.24. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$2.11 next year compared to a net loss per share of US$2.23 last year. Price Target Changed • Apr 27
Price target decreased to US$8.67 Down from US$20.00, the current price target is an average from 5 analysts. New target price is 381% above last closing price of US$1.80. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year. Price Target Changed • Apr 12
Price target decreased to US$9.40 Down from US$20.00, the current price target is an average from 5 analysts. New target price is 300% above last closing price of US$2.35. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$2.28 next year compared to a net loss per share of US$2.23 last year. Price Target Changed • Apr 09
Price target increased to US$23.00 Up from US$21.33, the current price target is an average from 5 analysts. New target price is 621% above last closing price of US$3.19. Stock is down 87% over the past year. The company is forecast to post a net loss per share of US$2.35 next year compared to a net loss per share of US$2.23 last year. Price Target Changed • Mar 02
Price target increased to US$23.00 Up from US$21.33, the current price target is an average from 4 analysts. New target price is 389% above last closing price of US$4.70. Stock is down 52% over the past year. The company is forecast to post a net loss per share of US$2.39 next year compared to a net loss per share of US$2.23 last year. Price Target Changed • Feb 10
Price target decreased to US$21.33 Down from US$24.50, the current price target is an average from 5 analysts. New target price is 242% above last closing price of US$6.23. Stock is down 57% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year. Price Target Changed • Feb 02
Price target decreased to US$23.33 Down from US$25.67, the current price target is an average from 5 analysts. New target price is 246% above last closing price of US$6.75. Stock is down 42% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year. Price Target Changed • Dec 24
Price target decreased to US$25.67 Down from US$28.67, the current price target is an average from 5 analysts. New target price is 134% above last closing price of US$10.98. Stock is up 37% over the past year. The company is forecast to post a net loss per share of US$2.21 next year compared to a net loss per share of US$2.08 last year. Breakeven Date Change • May 14
Forecast to breakeven in 2025 The 4 analysts covering Rubius Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$52.0m in 2025. Average annual earnings growth of 24% is required to achieve expected profit on schedule. Recent Insider Transactions Derivative • Mar 18
Insider exercised options and sold US$313k worth of stock On the 15th of March, Maiken Keson-Brookes exercised 25k options at a strike price of around US$7.70 and sold these shares for an average price of US$20.24 per share. This trade did not impact their existing holding. As of today, Maiken currently holds no shares directly. Company insiders have collectively sold US$86k more than they bought, via options and on-market transactions in the last 12 months. Is New 90 Day High Low • Mar 10
New 90-day high: US$15.01 The company is up 95% from its price of US$7.71 on 09 December 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. Price Target Changed • Feb 25
Price target raised to US$13.25 Up from US$11.50, the current price target is an average from 5 analysts. The new target price is 19% above the current share price of US$11.18. As of last close, the stock is up 38% over the past year. Recent Insider Transactions Derivative • Feb 12
Executive Chairman notifies of intention to sell stock David Epstein intends to sell 200k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of February. If the sale is conducted around the recent share price of US$14.93, it would amount to US$3.0m. Since March 2020, David has owned 4.82m shares directly. Company insiders have collectively bought US$285k more than they sold, via options and on-market transactions, in the last 12 months. Is New 90 Day High Low • Jan 26
New 90-day high: US$10.00 The company is up 115% from its price of US$4.65 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 27% over the same period. Price Target Changed • Jan 20
Price target raised to US$10.29 Up from US$9.43, the current price target is an average from 5 analysts. The new target price is 8.2% above the current share price of US$9.51. As of last close, the stock is up 12% over the past year. Is New 90 Day High Low • Jan 08
New 90-day high: US$8.83 The company is up 62% from its price of US$5.45 on 09 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. Is New 90 Day High Low • Dec 15
New 90-day high: US$8.73 The company is up 72% from its price of US$5.09 on 15 September 2020. The American market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Nov 24
New 90-day high: US$5.92 The company is up 17% from its price of US$5.05 on 25 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Oct 21
New 90-day low: US$4.62 The company is down 18% from its price of US$5.63 on 23 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Sep 24
New 90-day low: US$4.75 The company is down 20% from its price of US$5.93 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.